Marrone Bio Warrant Holders Exercise Final Tranche, Eliminating Warrant Overhang

Rhea-AI Summary

During November and December 2021, Marrone Bio Innovations (NASDAQ: MBII) completed the exercise of the final tranche of warrants, generating $3.5 million in cash and increasing its outstanding shares by 4.7 million. The elimination of the majority of unexercised warrants provides the company with enhanced financial flexibility, according to CEO Kevin Helash. This development supports ongoing product advancement and strengthens the company’s capital structure as it approaches the 2022 fiscal year and agricultural season.

Positive

• Generated $3.5 million in cash from warrant exercises.
• Eliminated majority of unexercised warrants, improving capital structure.
• Enhanced financial flexibility supports ongoing product development.

Negative

• None.

DAVIS, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- During November and December 2021, certain warrant holders in Marrone Bio Innovations, Inc. (NASDAQ: MBII) completed the exercise of the fifth and final tranche of warrants, generating a total of $3.5 million in cash during the fourth quarter of 2021 and increasing the company’s outstanding shares by 4.7 million. With these exercises, and the December 15, 2021, expiration of the substantial majority of the company’s other unexercised warrants, the company’s material warrant overhang has been eliminated.

“The support of our investors through their warrant exercises has provided the company with additional financial flexibility beyond our ongoing generation of cash from operations,” said Chief Executive Officer Kevin Helash. “As a result, we have accelerated the advancement of key products in our research and development pipeline while continuing to expand our global commercial footprint.

“The elimination of the warrant overhang is a positive for our capital structure as we move into the 2022 fiscal year and agricultural growing season,” Helash added.

About Marrone Bio Innovations     

Marrone Bio Innovations Inc. (NASDAQ: MBII) is a growth-oriented agricultural company leading the movement to environmentally sustainable farming practices through the discovery, development and sale of innovative biological products for crop protection, crop health and crop nutrition. Our portfolio of 18 products helps customers operate more sustainably while increasing their return on investment. The company’s commercial products are sold globally and supported by a robust portfolio of more than 500 issued and pending patents.  Our end markets include row crops; fruits and vegetables; trees, nuts and vines; and greenhouse production. Marrone Bio’s research and development program uses proprietary technologies to isolate and screen naturally occurring microorganisms and plant extracts to create new, environmentally sound solutions in agriculture.

Learn more about Marrone Bio Innovations at www.marronebio.com. We also use our investor relations website, https://investors.marronebio.com, as well as our corporate Twitter account, @Marronebio, as means of disclosing material non-public information, and encourage our investors and others to monitor and review the information we make public in these locations. Follow us on social media: Twitter, LinkedIn and Instagram.

Marrone Bio Innovations Forward Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding strategy, product development, future operations and plans, including assumptions underlying such statements, are forward-looking statements, and should not be relied upon as representing the company’s views as of any subsequent date. Examples of such statements include expectations regarding advancement of key products, expansion of the company’s global footprint and anticipated benefits to the warrant exercises on the company’s capital structure. Such forward-looking statements are based on information available to the company as of the date of this release and involve a number of risks and uncertainties, some beyond the company’s control, that could cause actual results to differ materially from those anticipated by these forward-looking statements, including the recent uncertainty in the global economy and industry-specific economy caused by the COVID-19 pandemic, consumer, regulatory, weather and other factors affecting demand for the company’s products, any difficulty in expanding the company’s sales and marketing infrastructure or marketing the company’s products in global markets, competition in the market for herbicide products, lack of understanding of bio-based herbicide products by customers and growers, adverse actions by distributors, manufacturers, regulatory agencies and other relevant third parties. Additional information that could lead to material changes in the company’s performance is contained in its filings with the Securities and Exchange Commission. The company is under no obligation to, and expressly disclaims any responsibility to, update or alter forward-looking statements contained in this release, whether as a result of new information, future events or otherwise.

Marrone Bio Innovations Contact:
Clyde Montevirgen
Vice President of Business Development & Investor Relations
Telephone: 530-750-2800
info@marronebio.com

FAQ

What financial impact did the warrant exercises have on Marrone Bio Innovations (MBII)?

The warrant exercises generated $3.5 million in cash and increased outstanding shares by 4.7 million.

How does the elimination of warrant overhang affect MBII's capital structure?

It improves MBII's capital structure, providing better financial flexibility moving into 2022.

What are the future implications of the cash generated from the warrant exercises for MBII?

The cash will support the advancement of key products in their R&D pipeline and expansion efforts.